
    
      This multicentre phase II clinical trial will target adults and children with fullt-thickness
      skin defects to elucidate the benefit of a tissue-engineered autologous skin substitute.
      Particular emphasis, apart from safety, will be placed on efficacy, e.g. scar quality, in
      comparison to meshed STSG.
    
  